[{"id":"93251c54-8adb-447a-9973-35caed693d12","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022861","created_at":"2023-09-05T18:12:23.926Z","updated_at":"2024-07-02T16:35:14.731Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT06022861","lead_sponsor":"Shandong Boan Biotechnology Co., Ltd","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • 5-fluorouracil • BA1104 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-15"}]